15 Jan, 2025
\n \n \n \nU-Ploid, a venture-backed biotechnology company developing next-generation fertility therapeutics, is pleased to announce the appointment of Professor Alison Campbell to its Advisory Board. In this key role, Professor Campbell will provide strategic guidance on company research programmes, working closely with the U-Ploid team to drive innovation in fertility treatments.
\n \n\n \n \n9 Jan, 2025
\n \n \n \nDr. Heinrich Roder, expert in lung cancer proteomics liquid biopsy, appointed as Senior Vice President of Research and Development at OXcan.
\n \n\n \n \n28 Nov, 2024
\n \n \n \nTechBio startup, Exogene, is leveraging artificial intelligence (AI) to develop innovative immunotherapies with the potential to eliminate untreatable solid tumours in cancer patients. Through a collaboration with German company Alithea Bio, Exogene hopes to speed up cancer immunotherapy discovery and make it more cost-effective.
\n \n\n \n \n11 Nov, 2024
\n \n \n \nThrough UK-Germany Collaborative R&D funding, Exogene is collaborating with the German company Alithea Bio, aiming to accelerate cancer immunotherapy discovery and make it more cost-effective.
\n \n\n \n \n8 Nov, 2024
\n \n \n \nInfinitopes, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announces that it will be presenting three posters on its pioneering cancer vaccine discovery and development, including one that has been recognised as a \u2018top 100\u2019 poster presentation, at the Society for Immunotherapy of Cancer (SITC) 2024, held in Houston, US, from 6-10th November.
\n \n\n \n \n28 Aug, 2024
\n \n \n \nWe are excited to welcome Eterna Biologics, a University of Oxford biotech spinout company with a mission to unleash the full potential of RNA medicines. The company aims to enhance global health by expanding the applicability of RNA-targeting medicine to develop treatment for a wide range of human conditions.
\n \n\n \n \n23 Aug, 2024
\n \n \n \nThe team of University of Oxford students is making strides that could transform our approach to antibiotics.
\n \n\n \n \n21 Aug, 2024
\n \n \n \nU-Ploid Biotechnologies joins the BioEscalator to develop groundbreaking therapeutics that improve egg quality and revolutionise IVF.
\n \n\n \n \n19 Jul, 2024
\n \n \n \nWe are delighted to welcome RE-AIM Therapeutics to the BioEscalator community, a start-up focused on developing antibody-based curative therapies for inflammatory disorders, such as psoriasis and inflammatory bowel disease.
\n \n\n \n \n19 Jul, 2024
\n \n \n \nSiGenex is advancing genomic medicine with its innovative, artificial intelligence-powered in-hospital sequencing platform. The company's technology is designed to transform how hospitals, clinics, and medical centres perform targeted next-generation sequencing (NGS) tests.
\n \n\n \n \n18 Jul, 2024
\n \n \n \nBioarchitech's departure from the BioEscalator marks the beginning of an exciting new phase for the pioneering cancer therapy company, as it transitions to the next stage of its innovative journey.
\n \n\n \n \n3 Jul, 2024
\n \n \n \nIn April 2024, the BioEscalator welcomed Granza Bio, a biotech startup focusing on developing novel immunotherapy delivery methods. The company has already attracted investor interest and closed a successful $7.14 million seed funding round led by Felicis and Refactor, with participation from Y Combinator.
\n \n\n \n \n5 Jun, 2024
\n \n \n \nMediMab Biotherapeutics announces its graduation from the BioEscalator. This move represents a major milestone for the company as it relocates to Abingdon Science Park, positioning itself for further expansion and cutting-edge research in immuno-oncology.
\n \n\n \n \n30 Apr, 2024
\n \n \n \nFunding also supports the start of phase I/IIa study for lead vaccine, ITOP1
\n \n\n \n \n3 Apr, 2024
\n \n \n \nThe BioEscalator is pleased to welcome Granza Bio, a biotech startup founded by two PhD graduates in oncology and immunology from the University of Oxford. Granza Bio is pioneering a new era in cancer therapeutics by developing personalised and targeted cancer treatments using the body's own immune system.
\n \n\n \n \n4 Mar, 2024
\n \n \n \nExogene, a pioneer in the use of generative artificial intelligence (AI) for T-cell receptor (TCR) engineering, has entered into a research collaboration with industry leader Immunocore Holdings plc (NASDAQ: IMCR), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases.
\n \n\n \n \n23 Nov, 2023
\n \n \n \nThe OBN Awards recognise companies that demonstrate outstanding leadership, innovative practices, and significant contributions towards addressing clinical needs at different stages of development.
\n \n\n \n \n29 Sep, 2023
\n \n \n \nWe are delighted that BioEscalator resident start-up Hutano Diagnostics has announced its acquisition by Cambridge, UK-based EDX Medical Group PLC.
\n \n\n \n \n29 Sep, 2023
\n \n \n \nDespite facing tough competition, Oxford Silk Phage Technologies impressed the judges with its presentation, earning the top spot in the competition.
\n \n\n \n \n5 Dec, 2022
\n \n \n \nAlethiomics is uncovering new biology to discover and develop life-changing treatments for patients with blood cancer, and Infinitopes is identifying hidden tumour targets, enabling the creation of high-efficiency vaccines.
\n \n\n \n \n